AstraZeneca PLC discovers, develops, manufactures, and markets prescription pharmaceuticals, biologics, and vaccines in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. Its products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related diseases; Seroquel, an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania; and Symbicort for the maintenance treatment of asthma in patients. The company also engages in the research, development, manufacture, and marketing of medical devices and implants for use in urology, surgery, and odontology. In addition, it develops and manages hospital-based outpatient cancer centers in the United States; and produces individually adapted abutments for dental implants using a patented CAD/CAM method. AstraZeneca markets its products to primary care and specialist physicians, as well as to other healthcare professionals, governments, and healthcare buying groups through sales and marketing network, local marketing companies, distributors, or local representative offices. It has strategic alliances with Bristol-Myers Squibb Company; WuXi Pharmatech Co., Ltd; and ChemBridge, as well as a strategic partnership with Peking University Third Hospital. The company also has collaborations with Palatin Technologies, Inc.; Schering AG; Targacept, Inc.; Abbott Laboratories; Silence Therapeutics plc; University of Texas Southwestern Medical Center; and Argenta Discovery Limited. AstraZeneca was founded in 1992. It was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999. The company is headquartered in London, the United Kingdom.